Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Karim Fizazi, NamPhuong Tran, Luis Fein et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer

Ryan Phillips, William Y. Shi, Matthew P. Deek et al. · JAMA Oncology · 2020 · 1.1K citations · Full text

Medicine, Oncology, Urology +17

Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

Maha Hussain, Catherine M. Tangen, Donna L. Berry et al. · New England Journal of Medicine · 2013 · 568 citations · Full text

Medicine, Oncology, Urology +14

Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer

Chad Tang, Alexander D. Sherry, Cara Haymaker et al. · JAMA Oncology · 2023 · 201 citations · Full text

Medicine, Oncology, Urology +17

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

Fred Saad, Eleni Efstathiou, Gerhardt Attard et al. · The Lancet Oncology · 2021 · 106 citations · Full text

Medicine, Oncology, Urology +16